Skip to content

The efficacy and safety of HA380 hemoadsorption for early refractory septic shock: an open-label, randomized controlled multicenter study

The efficacy and safety of HA380 hemoadsorption for early refractory septic shock: an open-label, randomized controlled multicenter study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600126183
Enrollment
Unknown
Registered
2026-06-04
Start date
2026-06-05
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Septic shock

Interventions

Control group:Conventional therapy of septic shock plus continuous veno-venous hemofiltration
HA380 Group:Conventional therapy of septic shock +continuous veno-venous hemofiltration+HA380 hemoperfusion

Sponsors

Shandong Provincial Hospital Affiliated to Shandong First Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients with refractory septic shock and acute kidney injury requiring renal replacement therapy within 24 hours of septic shock onset; 2. Age >=18 years; 3. Serum IL-6 >=300 pg/mL; 4. Weight >=40 kg.

Exclusion criteria

Exclusion criteria: 1.Patients with severe chronic organ failure, such as chronic heart failure (NYHA class IV), chronic liver failure (Child-Pugh class C), chronic renal failure (eGFR<15ml/min/1.73m2); 2.Patients with an expected survival time = 24 hours; 3.Patients who need to undergo plasma exchange, double plasma exchange or double plasma molecular adsorption system treatment or other blood purification treatment; 4.Patients with other types of shock at the same time, such as cardiogenic shock, obstructive shock and hypovolemic shock; 5.Patients who received hemadsorption, hemofiltration or other blood purification treatments within 3 days before enrollment; 6.Hemadsorption therapy cannot be initiated: patients with platelet count < 20*109/L or those with contraindications to anticoagulation; 7.Pregnancy or lactation; 8.Acquired immune deficiency syndrome and human immunodeficiency virus carriers; 9.Treating team deems enrolment in the study is not in the best interest of the patient.

Design outcomes

Primary

MeasureTime frame
Time to shock reversal ;

Secondary

MeasureTime frame
vasopressor dependency index;Cytokines;28-day all-cause mortality;

Countries

China

Contacts

Public ContactJinjiao Jiang

Shandong Provincial Hospital Affiliated to Shandong First Medical University

jjjsch@163.com+86 531 6877 6432

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026